Literature DB >> 31288173

Combinational protective therapy for spinal cord injury medicated by sialic acid-driven and polyethylene glycol based micelles.

Xiao-Juan Wang1, Gao-Feng Shu2, Xiao-Ling Xu3, Chen-Han Peng3, Chen-Ying Lu4, Xing-Yao Cheng4, Xiang-Chao Luo4, Jie Li4, Jing Qi3, Xu-Qi Kang3, Fei-Yang Jin3, Min-Jiang Chen4, Xiao-Ying Ying3, Jian You3, Yong-Zhong Du5, Jian-Song Ji6.   

Abstract

Spinal cord injury (SCI) leads to immediate disruption of neuronal membranes and loss of neurons, followed by extensive secondary injury process. Treatment of SCI still remains a tremendous challenge clinically. Minocycline could target comprehensive secondary injury via anti-inflammatory, anti-oxidant and anti-apoptotic mechanisms. Polyethylene glycol (PEG), a known sealing agent, is able to seal the damaged cell membranes and reduce calcium influx, thereby exerting neuroprotective capacity. Here, an E-selectin-targeting sialic acid - polyethylene glycol - poly (lactic-co-glycolic acid) (SAPP) copolymer was designed for delivering hydrophobic minocycline to achieve combinational therapy of SCI. The obtained SAPP copolymer could self-assemble into micelles with critical micelle concentration being of 13.40 μg/mL, and effectively encapsulate hydrophobic minocycline. The prepared drug-loaded micelles (SAPPM) displayed sustained drug release over 72 h, which could stop microglia activation and exhibited excellent neuroprotective capacity in vitro. The SAPP micelles were efficiently accumulated in the lesion site of SCI rats via the specific binding between sialic acid and E-selectin. Due to the targeting distribution and combinational effect between PEG and minocycline, SAPPM could obviously reduce the area of lesion cavity, and realize more survival of axons and myelin sheaths from the injury, thus distinctly improving hindlimb functional recovery of SCI rats and conferring superior therapeutic effect in coparison with other groups. Our work presented an effective and safe strategy for SCI targeting therapy. Besides, neuroprotective capacity of PEG deserves further investigation on other central nervous system diseases.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neuroprotective; Polyethylene glycol; Sialic acid; Spinal cord injury; Targeting therapy

Year:  2019        PMID: 31288173     DOI: 10.1016/j.biomaterials.2019.119326

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Selenium-Doped Carbon Quantum Dots Efficiently Ameliorate Secondary Spinal Cord Injury via Scavenging Reactive Oxygen Species.

Authors:  Wenqi Luo; Yiming Wang; Feng Lin; Yixuan Liu; Rui Gu; Wanguo Liu; Chunsheng Xiao
Journal:  Int J Nanomedicine       Date:  2020-12-14

2.  Sodium alginate and naloxone loaded macrophage-derived nanovesicles for the treatment of spinal cord injury.

Authors:  Xiaoyao Liu; Xue Jiang; Qi Yu; Wenwen Shen; He Tian; Xifan Mei; Chao Wu
Journal:  Asian J Pharm Sci       Date:  2021-11-14       Impact factor: 6.598

3.  Thermo-sensitive electroactive hydrogel combined with electrical stimulation for repair of spinal cord injury.

Authors:  Wei Liu; Yiqian Luo; Cong Ning; Wenjing Zhang; Qingzheng Zhang; Haifeng Zou; Changfeng Fu
Journal:  J Nanobiotechnology       Date:  2021-09-23       Impact factor: 10.435

Review 4.  Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment.

Authors:  Filippo Pinelli; Fabio Pizzetti; Valeria Veneruso; Emilia Petillo; Michael Raghunath; Giuseppe Perale; Pietro Veglianese; Filippo Rossi
Journal:  Biomedicines       Date:  2022-07-12

5.  Epigallocatechin-3-gallate selenium nanoparticles for neuroprotection by scavenging reactive oxygen species and reducing inflammation.

Authors:  Yiming Wang; Wenqi Luo; Feng Lin; Wanguo Liu; Rui Gu
Journal:  Front Bioeng Biotechnol       Date:  2022-09-08

Review 6.  Targeting pulmonary vascular endothelial cells for the treatment of respiratory diseases.

Authors:  Yi-Xuan Li; Hong-Bo Wang; Jing Li; Jian-Bo Jin; Jing-Bo Hu; Chun-Lin Yang
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.